Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-04-26 Director's Dealing
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
FORM 6-K
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. The content is a notification of a director dealing, specifically reporting a transaction where a non-executive director received American Depositary Shares. The document includes details of the transaction, the director's name, and complies with the EU Market Abuse Regulation. It is not an annual report, earnings release, or any financial report but a report of personal share transactions by a company director. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3592 characters, which is consistent with a notification rather than a full report.
2019-04-26 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'Notification of Director Dealing' and explicitly details a transaction involving a non-executive director (Deepa Pakianathan) of Mereo BioPharma Group plc. It follows the standard format for reporting insider transactions under the EU Market Abuse Regulation, including the name of the person, their position, and the specific details of the financial instrument and transaction volume. This aligns perfectly with the definition for 'Director's Dealing'.
2019-04-26 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership by Woodford Investment Management Ltd in Mereo Biopharma Group PLC, crossing a significant threshold. This falls under the category of Major Shareholding Notification (MRQ).
2019-04-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership by Invesco Ltd. in Mereo Biopharma Group PLC, crossing a reporting threshold. This is a classic regulatory disclosure regarding major shareholding notifications, which aligns perfectly with the 'Major Shareholding Notification' (MRQ) category.
2019-04-25 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for Mereo BioPharma Group plc. It is a technical market announcement regarding trading parameters rather than a financial report, management update, or corporate action. As it does not fit into specific categories like dividends, share issues, or earnings, it falls under the general regulatory announcement category.
2019-04-25 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for Mereo BioPharma Group plc. It does not contain financial statements, management reports, or specific corporate actions like dividends or board changes. As it is a standard regulatory notification regarding trading parameters that does not fit into the other specific categories, it is classified as a Regulatory Filing (RNS).
2019-04-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.